Jeff Brown and the Brownstone Research team have launched a new promotion for The Near Future Report.
As part of that promotion, Jeff Brown “makes a stunning confession” about a technology that saved his life. He claims this technology “could be the #1 investment of 2021.”
By subscribing to The Near Future Report today, you can discover that #1 investment and get a bundle of bonus reports.
Is The Near Future Report worth the price? What will you learn in The Near Future Report? Find out everything you need to know about The Near Future Report and how it works today in our review.
What is The Near Future Report?
The Near Future Report is a financial analysis newsletter published by Jeff Brown and his Brownstone Research team.
The newsletter features investment recommendations, market analysis, investment guides, and more. You receive one new issue per month discussing the latest tech trends.
The Near Future Report is led by Jeff Brown, a former Silicon Valley technology executive with 25 years of experience. Jeff has predicted numerous tech trends and tech investments in the past. Now, he wants to share his wisdom with followers through The Near Future Report.
About Jeff Brown’s Stunning Confession
As part of a 2021 marketing campaign, Brownstone Research has released a sales page discussing Jeff Brown’s “stunning confession.”
By subscribing to The Near Future Report today, you can learn more about Jeff Brown’s stunning confession and its investment potential.
Jeff explains that technology in an interview with Chris Hurt. You can view that interview online or read the transcript.
In the interview, Jeff shares a confession about his health. Jeff thought he was a healthy person. However, after receiving a deep medical evaluation from a medical technology company, Jeff realized there was room for improvement:
“My name is Jeff Brown. And I have a confession to make. It’s something I haven’t shared publicly before now. You see, if it weren’t for one little-known technology, my life could have changed dramatically…I thought I was a perfectly healthy, 50-year-old man…I eat right…I exercise regularly. I’m active. I have a 3rd Degree Black Belt in Shotokan Karate. I had no reason to visit a doctor any time soon.”
Through his angel investing work, however, Jeff learned about a medical technology company based in California. Jeff claims this company is developing “groundbreaking technology” that will change the medical industry.
“…as an angel investor in Silicon Valley… I get to see all kinds of new technologies – before the rest of the market hears about them. That’s why I traveled thousands of miles to a small office in California. To visit a company whose groundbreaking technology is changing the medical industry.”
That company has a technology that performs a complete scan of your body, delivering unprecedented insights into your health.
By subscribing to The Near Future Report today, you get a bundle of bonus reports and investment guides.
Several of those guides focus on medical technology, including the technology created by this company. One guide focuses on a company making treatments for cystic fibrosis, for example, another precision medicine stock Jeff describes as the “king of genetic sequencing.”
Jeff’s secret confession is that the biotech company diagnosed him with prostate cancer, to make a long story short. After undergoing the scan, Jeff discovered he had the early stages of prostate cancer. This cancer would not have appeared on a blood test or a prostate exam, but it appeared on the biotech company’s advanced imaging report.
How Does the New Medical Technology Work?
Jeff claims a medical technology company saved his life by delivering unique insights into his health. So how does this unique medical technology work?
To be clear, Jeff claims this medical technology company does not endorse him, nor does he receive any compensation from this company.
Here are some crucial points Jeff realizes about the medical technology and how it works:
The company gave Jeff a full-body MRI using their state-of-the-art scanner, which he claims is “twice as strong” as the MRIs you see at most imaging centers and hospital centers.
That MRI created a remarkably clear image of Jeff’s body, creating over 150 gigabytes of data.
The company’s technology examines your entire body, down to the cellular level, in great detail.
Based on the scan, Jeff discovered he had prostate cancer. The cancer was in the early stages. It would not have been discovered with a simple prostate exam or a blood test. Because the scan identified cancer early, Jeff could treat it before it grew into a potentially deadly problem.
Because of Jeff’s personal experience with this medical technology, he believes it can change the world:
“…it’s an incredible new trend in medicine — driven by technology — that spotted cancer. And gave me a fighting chance to beat it super early — before it grew into a potentially deadly problem.”
Jeff doesn’t just recommend investing in this company to capitalize on this trend. Instead, he claims this company is just the tip of the iceberg of a $3.2 trillion industry that will change the world of medicine:
“But there’s more to this technology than just saving my life. It’s the tip of the iceberg of a $3.2 trillion breakthrough that I believe will change the way we look at medicine.”
By subscribing to The Near Future Report today, you can discover how this technology works, what it does, and why Jeff believes it will change the world of medicine.
How Much Money Can You Make?
As part of the new promotion, The Near Future Report dazzles investors with stories of making huge returns by investing in the right biotech or medical technology companies.
“There’s Biolife Sciences, which rose as high as 41,800% in less than a year…A small, $1,000 stake could have brought back as much as $418,000.”
The sales page is filled with similar gains. Jeff Brown uses Mirati Therapeutics as an example, which rose 8,481% in under two years.
Other gains featured on The Near Future Report’s sales page include:
- Elfato Inc., which rose 8,991%
- iBio, which rose 5,727%
- Castellum Inc, which rose 32,400%
- AXIM Biotechnologies, which rose 31,048%
Jeff Brown is careful to explain that past earnings do not guarantee future results. He also claims these are “speculative investments,” so they carry even more risk than ordinary investments. He does not recommend allocating a significant part of your portfolio to these stocks.
However, Jeff also claims he has “visited suppliers and done his own research on future earnings” to validate his recommendations. Based on that analysis, Jeff is confident that some of his biotech stock picks will rise substantially in the near future.
What is the $3.2 Trillion Industry that Could Save Millions of Lives?
Jeff, like many investors, believes biotech will be one of the hottest tech trends over the coming years. The biotechnology industry was sitting at $447.92 billion in 2019. It’s expected to grow to $833.34 billion by 2027.
Biotech is no secret. However, there are specific sectors within biotech that may be undervalued. Jeff mentions precision medicine as one example:
“…the biotech market is expected to grow 86% over the next few years. That is impressive. But listen to this…The precision medicine market is expected to grow 152% during that same time…”
Precision medicine is an emerging area of biotech that uses precise biological data to calculate disease risk. Precision medicine takes into account genes, environment, and lifestyle in each person to calculate disease risk. It’s hyper-customized medicine for people who want the most detailed health insights.
Examples of Precision Medicine
Jeff Brown cites numerous precision medicine examples delivering impressive results for patients – and big returns for investors.
Some of the examples featured on The Near Future Report’s sales page include:
One company used artificial intelligence to treat patients with obsessive-compulsive disorder. The drug was created entirely by artificial intelligence. AI sifted through tens of millions of possible molecules to determine the best drug candidates. That drug development took just 12 months to get to trial. This is the first time AI-created medicine will be used on humans. Drug discovery typically takes 3 to 6 years, so this is a swift trial time.
As another example, Jeff mentions an early-stage biotech company called AbCellera that used AI to slash antibody selection time for COVID-19. In March 2020, that company received a blood sample from a patient who recovered from COVID-19. AbCellera screened the blood sample for antibodies that could help people fight the virus. Typically, this process takes years. But AbCella screened more than 5 million immune cells in 11 days, identifying 350 antibodies effective against COVID-19.
Jeff mentions a company named Tempus that develops AI-enabled precision medicine software. That company raised $200 million in 2019 and 2020 and has raised more than $1 billion overall.
Caris Life Sciences is a molecular sciences company that recently secured $310 million in growth capital. That company will use that money to develop new healthcare technology initiatives.
By subscribing to The Near Future Report today, you can discover these biotech stocks and other healthcare technology stocks.
What’s Included with The Near Future Report?
As part of the new promotion, all subscriptions to The Near Future Report come with bonus reports, investment guides, and other analyses.
Here’s what you get by subscribing to The Near Future Report today:
Monthly Issues of The Near Future Report: Each month, Jeff Brown and his team identify new tech trends and tech investment opportunities. They travel through the United States to research the best opportunities, then share those opportunities with investors. Each monthly issue features stock recommendations, investment ideas, market news and analysis, and more from the world of technology.
Access to Past and Future Reports: All subscribers to The Near Future Report get access to past and future reports, including any additional guides released by Brownstone Research.
Access to Members-Only Portfolio: The Near Future Report subscribers receive access to a portfolio where you can view all recommended stocks from the team, including the price of those stocks, the entry and exit points, and more. You can make the same gains as Jeff Brown and his team by investing in the exact stocks they recommend based on the model portfolio.
Customer Service: Subscribers get access to the US-based customer service team, available Monday to Friday from 9 am to 7 pm ET.
Bonus Report #1: The #1 Precision Medicine Stock of the 2020s: Why the FDA Just Fast-Tracked the “King of Genetic Sequencing”: In this report, Jeff explains how precision medicine works and why it could be one of the biggest biotech investing trends in the coming years. Jeff claims one precision medicine company’s technology saved his life by identifying his prostate cancer early. He claims a small investment in this stock today could create huge returns for investors in the future.
Bonus Report #2: The Company Behind Cystic Fibrosis’ Demise: Biotech companies seek to cure conditions like cystic fibrosis. Jeff believes one company is on the cusp of eliminating cystic fibrosis. By investing in this company today, you can reap huge rewards if the company is successful.
Bonus Report #3: My #1 Stock “Behind Quantum Computing’s Rise: In this report, Jeff describes how quantum computers could deliver huge returns for investors. Quantum computers are 100 million times faster than ordinary computers. If quantum computers are successful, they could transform AI. AI is often held back by limited processing power: there’s only so much data that AI can process on today’s systems. Jeff recommends one specific quantum computing stock that has solved quantum computing issues – like the error-prone nature of quantum computing.
Bonus Report #4: My #1 Gene Therapy Stock: Gene therapy is a new medicine field where researchers deliver a new working gene into a cell to make the cell do what it’s supposed to do. Jeff recommends investing in one specific gene therapy stock he describes as “a world leader in the gene therapy sector.” In this report, Jeff explains how this gene therapy works, why it could create huge gains for investors, and how this industry will change over the coming years.
The Near Future Report Pricing
As part of the 2021 promotion, you can subscribe to The Near Future Report for just $49 today. Then, one year after you pay for your subscription, you’ll receive a new year for $129.
Here’s how pricing breaks down:
- Annual Subscription: $49 for your first year, $129 per year thereafter
You can cancel your subscription at any time.
The Near Future Report Refund Policy
A 60-day moneyback guarantee backs the Near Future Report.
If you’re unhappy with the information provided in The Near Future Report for any reason, then you can request a complete refund within 60 days of your original subscription date.
Contact Brownstone Research to initiate the refund process.
About Jeff Brown
Jeff Brown is an angel investor and former technology company executive. Today, Jeff seeks to use his 25 years of experience in Silicon Valley to identify the next big tech trends.
Jeff is the founder of Brownstone Research and works as editor of multiple newsletters – including The Near Future Report.
About Brownstone Research
Brownstone Research is a financial publishing company launched by Jeff Brown. The company offers a range of free and paid newsletters for investors, including The Near Future Report, The Bleeding Edge, Exponential Tech Investor, and Blank Check Speculator.
You can contact Brownstone Research via the following:
- Email: email@example.com
- Email Form: https://www.brownstoneresearch.com/contact-us/
- Phone: 1-888-493-3156
- Mailing Address: 55 NE 5th Avenue, Delray Beach, FL 33483
The Near Future Report is a financial newsletter that seeks to identify the next big tech trends. By subscribing to The Near Future Report today, you get a package of bonus reports and investment guides.
Jeff is a big believer in medical technology. He’s especially interested in precision medicine. In The Near Future Report’s bonus reports, you can discover specific investment recommendations from Jeff and his team, including precision medicine companies and biotech stocks Jeff expects to grow over the coming years.
The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.
Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.